
Vietnam · Biotechnology startup
GENETICA® US is a biotechnology company based in San Francisco, founded in 2017.
Funding reportedLast round: Seed
GENETICA® US is a biotechnology company based in San Francisco, founded in 2017.
It specializes in AI-powered genetic testing services tailored for the Asian population, with a strong focus on Southeast Asia, particularly Vietnam and Singapore, while also expanding into the United States. The company aims to enhance personal development and promote healthy living through precision medicine and personalized preventative care. The company offers low-cost saliva-based gene tests that analyze hundreds of genes and nearly one million variants. Their services include personalized reports on fitness and diet, child development, critical illness prevention, health risk assessments, and lifestyle recommendations. GENETICA® US utilizes a proprietary gene decoding chip developed in collaboration with Illumina® and Thermo Fisher Scientific, ensuring that their technology is specifically designed for Asian populations. With operational hubs in Vietnam and a commitment to customer support, GENETICA® US is recognized as a leading player in the direct-to-consumer gene testing market in Southeast Asia.
Funding, as reported
What they build
Known for
genetic report printinghealth carefitness scheme recommendationsgenetic analysis for education and healthconsumersdevelopment planninggenetic report reading guidegenetic health risk assessmentproprietary gene decoding technologygenetic testing privacy policygenetic testing for childrenhealth risk assessmentgenetic decoding chip for asiansgenetic potential analysis for childrengenetic testing for health and wellnessinformation technology & services
Built with from their website
Google Tag ManagerGoogle CloudYouTubeGoogle WorkspaceCloudFlareViewport MetaGoogle PlaywebpackFacebook SDKAmazon S3
Google Cloud HostingGoogle MeetCloudFlare CDNReactMobile FriendlyOpen GraphFacebook PixelSquarespace
Add your raise, your deck and your story, and put GENETICA US in front of investors. Or tell us what we have wrong.